ClinicalTrials.gg
RecruitingNCT07498673Updated May 12, 2026

A Study of YKST02 in Participants With Primary IgA Nephropathy

An Early Phase 1 interventional study of YKST02 in Primary IgA Nephropathy, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Planned enrollment
106th of 109
12 · median 84
Started
2026
with 24 others
Phase 1
21 of 127
13 open now
Primary completion
2027-03
later than 30 of 72 live
Registered
106th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 106th largest by planned enrollment of the 109 interventional ones that give a count, is one of 25 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 30 of the 72 other live ones, and was the 106th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety and tolerability of YKST02 and to explore its potential to treat adults with primary IgA nephropathy (IgAN). The study will also assess how the drug moves through the body and how it affects the immune system.

The main questions it aims to answer are:

  • Is YKST02 safe and well tolerated?
  • Does YKST02 reduce protein levels in the urine?
  • How does YKST02 behave in the body (pharmacokinetics, PK)?
  • How does YKST02 affect the immune system (pharmacodynamics, PD)? Participants are adults with IgAN who have persistent proteinuria despite standard treatment.

Participants will:

  • Receive YKST02 by intravenous (IV) infusion
  • Be monitored after each dose for safety
  • Attend clinic visits for safety assessments and laboratory tests
  • Provide blood and urine samples during the study and follow-up period
Read the detailed description

This is a single-center, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YKST02 in adults with primary IgA nephropathy (IgAN).

Eligible participants are adults with IgAN and persistent proteinuria despite standard-of-care treatment.

The study consists of a screening period, a treatment period, and a follow-up period. During the treatment period, YKST02 will be administered by intravenous infusion. Dose levels and dosing schedules may be adjusted based on safety, tolerability, and emerging data to support dose escalation and determination of an appropriate dose level.

Safety assessments will include monitoring of adverse events, clinical laboratory evaluations, vital signs, and other relevant clinical parameters. Pharmacokinetic evaluations will characterize the concentration-time profile of YKST02. Pharmacodynamic and biomarker assessments will evaluate the biological activity of YKST02 and its effects on immune-related pathways.

Immunogenicity will be assessed by evaluating anti-drug antibodies. Preliminary efficacy will be explored using clinical measures relevant to IgAN.

Additional exploratory analyses may be performed to further characterize immune-related biomarkers and potential effects on renal pathology, as applicable.

03

Conditions studied

  • Primary IgA Nephropathy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of primary IgA nephropathy (IgAN)
  • Proteinuria above a protocol-defined threshold at screening
  • Receiving stable standard-of-care therapy for IgAN for an adequate duration prior to enrollment, unless or not tolerated
  • Women of must have a negative pregnancy test prior to study drug administration and agree to use effective ; male participants must agree to use effective contraception
  • Able to understand the study procedures and provide written

Exclusion criteria

Exclusion Criteria:

  • Secondary IgA nephropathy (e.g., associated with liver disease, disorders, infections, or other systemic conditions)
  • Other renal diseases unrelated to IgAN (e.g., diabetic nephropathy, lupus nephritis, vasculitis)
  • Nephrotic syndrome considered unsuitable for study participation
  • Rapidly progressive glomerulonephritis or rapidly declining renal function
  • Estimated (eGFR) \<45 mL/min/1.73 m²
  • Immunodeficiency or low immunoglobulin G (IgG) levels below normal
  • Clinically significant abnormal laboratory findings (e.g., hematologic, hepatic, or coagulation abnormalities)
  • Requirement for systemic for concomitant conditions
  • Use of , targeted, or biologic therapies within a defined period prior to screening or anticipated use during the study
  • Prior treatment with B-cell-depleting or other targeted biologic therapies within a defined period
  • History of demyelinating disorders (e.g., multiple sclerosis)
  • Clinically significant cardiovascular or cerebrovascular disease within 6 months prior to screening
  • History of organ transplantation or planned transplantation during the study
  • Current dialysis or anticipated need for dialysis during the study
  • Major surgery within 4 weeks prior to screening or planned during the study
  • Active infection requiring systemic therapy, recent serious infection, or chronic/recurrent infections
  • Known active , , or (HIV) infection
  • Active or untreated latent tuberculosis
  • History of splenectomy
  • Uncontrolled comorbidities (e.g., poorly controlled hypertension or diabetes)
  • within the past 5 years, except adequately treated non-invasive cancers
  • Known to YKST02 or its components
  • Receipt of another product within 4 weeks or 5 half-lives (whichever is longer) prior to screening
  • Receipt of live or attenuated vaccines within 4 weeks prior to screening or planned during the study
  • Any condition that, in the investigator's judgment, would make the participant unsuitable for the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    YKST02

    Participants receive YKST02 administered by intravenous infusion in this single-arm, open-label, dose-escalation study. Participants receive an initial dosing phase followed by subsequent administrations at escalating dose levels. Dose levels and dosing schedules may be adjusted based on safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) data. A follow-up period is included for safety and efficacy assessments.

    Drug: YKST02

Interventions

  • DrugYKST02

    YKST02 is an investigational drug administered by intravenous infusion. It is provided as a sterile formulation for clinical use. Dosing may vary based on study design and ongoing evaluation of safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) data.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Safety will be assessed by the incidence and severity of adverse events (AEs) and serious adverse events (SAEs).

    Time frame: From first dose through Week 25

  2. Change from Baseline in UPCR

    Efficacy will be evaluated by the change from baseline in urine protein-to-creatinine ratio (UPCR).

    Time frame: From baseline through Week 25

  3. Change from Baseline in eGFR

    Efficacy will be evaluated by the change from baseline in estimated glomerular filtration rate (eGFR).

    Time frame: From baseline through Week 25

  4. Change from Baseline in Urinary Red Blood Cells

    Efficacy will be evaluated by the change from baseline in urinary red blood cells.

    Time frame: From baseline through Week 25

Secondary outcomes

  1. Area Under the Concentration-Time Curve (AUC) of YKST02

    Area under the concentration-time curve (AUC), including AUC0-t and AUC0-∞, of YKST02 will be evaluated.

    Time frame: From first dose through Week 25

  2. Maximum Observed Concentration (Cmax) of YKST02

    Maximum observed plasma concentration (Cmax) of YKST02 will be evaluated.

    Time frame: From first dose through Week 25

  3. Half-life (t1/2) of YKST02

    Terminal elimination half-life (t1/2) of YKST02 will be evaluated.

    Time frame: From first dose through Week 25

  4. Change from Baseline in Gd-IgA1

    Pharmacodynamic effects will be evaluated by the change from baseline in galactose-deficient IgA1 (Gd-IgA1).

    Time frame: From baseline through Week 24.

  5. Change from Baseline in Serum Immunoglobulin Levels

    Changes from baseline in serum immunoglobulin levels will be assessed, including IgA, IgG, and IgM.

    Time frame: From baseline through Week 24

  6. Change from Baseline in Complement Levels

    Changes from baseline in complement levels will be assessed, including complement components C3 and C4.

    Time frame: From baseline through Week 24

  7. Immunogenicity of YKST02

    Immunogenicity will be assessed by the incidence of anti-drug antibodies (ADAs). Neutralizing antibodies (NAbs) will be evaluated in participants who are ADA-positive.

    Time frame: From baseline through Week 25

  8. Changes in Lymphocyte Subsets

    Changes from baseline in peripheral blood lymphocyte subsets will be assessed, including B cell subsets and T cell subsets.

    Time frame: From baseline through Week 24

  9. Changes in Lymphocyte Activation Markers

    Changes from baseline in activation status of lymphocyte populations will be assessed using relevant activation markers, as applicable.

    Time frame: From baseline through Week 24

  10. Changes in Cytokine Levels

    Changes from baseline in cytokine levels relevant to immune and inflammatory responses will be assessed.

    Time frame: From baseline through Week 24

Other outcomes

  1. Changes in Renal Histopathology

    Pre-specified analyses will include evaluation of renal biopsy samples using histopathological methods.

    Time frame: From baseline through Week 24

  2. Changes in Immune-Related Biomarkers

    Pre-specified analyses will include assessment of immune-related biomarkers, such as gene expression profiles and immune repertoire characteristics.

    Time frame: From baseline through Week 24

07

Study locations

1 of 1 sites recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Qiubai Li, MD, PhD · Contactqiubaili@hust.edu.cn · +86-027-85726338
    • Qiubai Li, MD, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 10 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Mar 27, 2026
StartActual
May 6, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jun 30, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07498673
Responsible party
Qiubai Li (Professor and Chief Physician, Head of Rheumatology Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Mar 27, 2026
Start date
May 6, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 12, 2026

Study contacts

Qiubai Li, MD, PhD
Contact
qiubaili@hust.edu.cn
+86-27-85726338

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: YKST02

Start the discussion